First GPCR target nominated for therapeutic development under Sosei and Kallyope’s GI collaboration
Nov. 10, 2023
Sosei Group Corp. and Kallyope Inc. have announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal (GI) diseases. The nominated target will advance into a structure-based drug discovery program.